Wauwatosa, WI, June 23, 2014 - GE Healthcare, (NYSE: GE), announced today clearance from the Food and Drug Administration (FDA) for its new Vivid T8TM cardiovascular ultrasound device. The 129-pound, mobile system features innovative quantitative features, stress echo and TEE capabilities, delivering exceptional value to healthcare providers looking for an affordable echo system.
Princeton, NJ -- May 30, 2014 -- Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for the production of sodium pertechnetate; technetium (Tc99m) injection to its radiopharmacies in the US.
business unit
tags
Wauwatosa, WI, October 10, 2013 - GE Healthcare, (NYSE: GE), announced today clearance from the Food and Drug Administration (FDA) for the latest version of its Vivid E9 Cardiovascular Ultrasound system now featuring XDclear technology.
business unit
tags
Wauwatosa, WI and Amsterdam, Netherlands, September 1, 2013 - GE Healthcare, (NYSE: GE), announced today at the 2013 European Society of Cardiology annual meeting in Amsterdam that it has received CE mark for the latest version of its Vivid E9 Cardiovascular Ultrasound system now featuring XDclear technology.